1441 completed, 289 unknown, 274 terminated, 272 recruiting. 2640 Phase 3, 350 Phase 2.
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 10 | 2028-09-01 | 2026-11-12 |
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease | Phase 3 | Withdrawn | Vertex Pharmaceuticals Incorporated | 2027-07-31 | 2026-03-25 | |
| A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) Roxadustat, Placebo - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Kyntra Bio | 201 | 2027-04-01 | 2026-07-23 |
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-10-29 |
| A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients. FXS6837 Capsule - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 20 | 2027-01-26 | 2026-11-04 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 300 | 2026-12-30 | 2026-11-12 |
| Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A FRSW107 - Severe Hemophilia A | Phase 3 | Not yet recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 76 | 2026-12-25 | 2024-06-20 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Not yet recruiting | Janssen Research & Development, LLC | 1000 | 2026-12-14 | 2026-11-04 |
| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. FXS6837 Capsule, Eculizumab infusion - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 90 | 2026-12-10 | 2026-08-05 |
| A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®] - Iron Deficiency Anemia (IDA) | Phase 3 | Not yet recruiting | AFT Pharmaceuticals, Ltd. | 1366 | 2026-12-01 | 2026-08-20 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
Showing 20 of 2640. Sign in to see all of them.
Multiple Myeloma (384) · Anemia (371) · Leukemia, Myeloid, Acute (330) · Leukemia (220) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (198) · Leukemia, Lymphocytic, Chronic, B-Cell (176) · Hemophilia A (157) · Myelodysplastic Syndromes (151) · Purpura, Thrombocytopenic, Idiopathic (120) · Lymphoma (111) · Anemia, Sickle Cell (107) · Neoplasms (97) · Anemia, Iron-Deficiency (92) · Hematologic Neoplasms (89)
Hemic and Lymphatic Diseases (2639) · Neoplasms (1229) · Neoplasms by Histologic Type (1165) · Immune System Diseases (992) · Hemorrhagic Disorders (808) · Immunoproliferative Disorders (767) · Lymphoproliferative Disorders (761) · Pathological Conditions, Signs and Symptoms (759) · Pathologic Processes (709) · Leukemia (582) · Cardiovascular Diseases (511) · Vascular Diseases (499) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (484) · Disease Attributes (465)
Dexamethasone (279) · Cytarabine (197) · Cyclophosphamide (195) · Bortezomib (115) · Lenalidomide (112) · Daunorubicin (102) · Methotrexate (99) · Etoposide (84) · Vincristine (84) · Rituximab (81) · Prednisone (77) · fludarabine (74) · venetoclax (72) · Azacitidine (71) · Doxorubicin (70)
Hoffmann-La Roche (76) · Novartis Pharmaceuticals (63) · Amgen (59) · Children's Oncology Group (40) · Pfizer (40) · Assistance Publique - Hôpitaux de Paris (37) · Celgene (37) · GlaxoSmithKline (36) · Janssen Research & Development, LLC (34) · Baxalta now part of Shire (31) · National Cancer Institute (NCI) (31) · CSL Behring (28) · The First Affiliated Hospital of Soochow University (28) · Nanfang Hospital, Southern Medical University (27) · Novo Nordisk A/S (25)
United States (1142) · France (636) · Germany (628) · Italy (585) · United Kingdom (577) · Spain (541) · Canada (528) · China (440) · Australia (421) · Poland (418) · Belgium (371) · Netherlands (320) · Czechia (315) · Austria (308) · Japan (306)
Qifa Liu (13)
PMID 36005278, PMID 36791280, PMID 26965694, PMID 34932836, PMID 41114449, PMID 33242441, PMID 40750723, PMID 22689675, PMID 37975597, PMID 38620092, PMID 39121442, PMID 19216617, PMID 23343061, PMID 23343062, PMID 26196195, PMID 31221778, PMID 34289038, PMID 35244208, PMID 35829925, PMID 35939785, PMID 36749544, PMID 37254256, PMID 37267439, PMID 37341189, PMID 38363466, PMID 39393433, PMID 40266025, PMID 40359056, PMID 19005182, PMID 19671919, PMID 20175775, PMID 22965967, PMID 23007406, PMID 23897961, PMID 24970932, PMID 26931631, PMID 28751558, PMID 31196847, PMID 31203241, PMID 31375516, PMID 33131249, PMID 33783815, PMID 33995988, PMID 34219224, PMID 34362786, PMID 34865212, PMID 34922648, PMID 35985959, PMID 36184192, PMID 36815378
2023 (76), 2016 (41), 2014 (34), 2017 (34), 2025 (30), 2015 (29), 2019 (27), 2009 (26), 2018 (25), 2008 (19), 2005 (16), U10CA021115 (16), U10CA098543 (16), U10CA180820 (12), U10CA180886 (12)